Abstract
Background: Although the interleukin-1 receptor antagonist (IL-lra) has been suggested as a potentially valuable therapeutic agent and has been shown to improve outcome in various animal models of arthritis, septic shock, and inflammatory bowel disease, there is little information available about its level in the circulation in patients with cancer. Methods: Serum levels of IL-lra, soluble interleukin-2 receptor (sIL-2r), soluble intercellular adhesion molecule-1 (sICAM-1), and Cortisol were measured in normal controls and patients with colorectal cancer. Results: The data showed that serum IL-lra levels in patients were significantly lower than those of healthy controls (P < 0.05). In contrast, serum sIL-2r and Cortisol levels in patients were significantly higher than those of normal controls (P < 0.01). Serum sICAM-1 levels in patients were the same as in normal controls. Conclusions: These results suggested that a reduced level of IL-lra exists in colorectal cancer patients relative to normal controls, indicating that cancer patients have an immunologic disorder and that exogenous IL-lra administration might be a future alternative for cancer treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
